mannosebind
lectin
mbl
target
divers
microorgan
phagocytosi
complementmedi
lysi
bind
specif
surfac
glycan
although
recombin
human
mbl
rhmbl
trial
focus
reconstitut
therapi
safeti
studi
identifi
barrier
use
higher
level
ebola
virus
caus
fatal
hemorrhag
fever
treatment
exist
fear
potenti
biothreat
agent
found
mice
whose
rhmbl
serum
concentr
increas
averag
human
level
surviv
otherwis
fatal
ebola
viru
infect
becam
immun
viru
rechalleng
ebola
glycoprotein
potenti
model
glycosyl
virus
rhmbl
may
offer
novel
broadspectrum
antivir
approach
circul
mannosebind
lectin
mbl
firstlin
host
defens
wide
rang
viral
pathogen
mbl
ctype
lectin
recogn
hexos
sugar
includ
mannos
glucos
fucos
nacetylglucosamin
surfac
mani
pathogen
recogn
termin
carbohydr
galactos
sialic
acid
normal
host
cell
therefor
mbl
preferenti
recogn
glycosyl
virus
includ
influenza
viru
human
immunodefici
viru
sever
acut
respiratori
syndrom
coronoviru
sarscov
ebola
viru
marburg
viru
also
recogn
mani
glycosyl
gramposit
gramneg
bacteria
result
common
genet
variant
mbl
serum
level
human
rang
ngml
thirti
percent
human
popul
level
ngml
associ
increas
suscept
infect
children
immunocompromis
individu
previous
report
preclin
studi
address
potenti
util
recombin
human
mbl
rhmbl
reconstitut
therapi
mblknockout
mice
highli
suscept
sever
bacteria
includ
staphylococcu
aureu
rhmbl
improv
surviv
mblnull
mice
approxim
surviv
among
infect
wildtyp
mice
dose
reconstitut
complementactiv
capac
mblknockout
serum
level
compar
wildtyp
mous
serum
dose
plasmaderiv
mbl
rhmbl
design
increas
mbl
concentr
physiolog
level
ngml
mbldefici
human
safe
earli
trial
elicit
antibodi
contrast
although
mbl
replac
therapi
enhanc
opsonophagocyt
potenti
higher
level
plasmaderiv
mbl
need
achiev
mblmediat
complement
activ
compar
healthi
control
suggest
abovereplac
dose
need
attent
ebola
marburg
virus
filoviru
famili
among
virul
caus
human
viral
hemorrhag
fever
caus
devast
epidem
fulmin
rapidli
fatal
diseas
constitut
import
biolog
threat
agent
high
mortal
rate
capac
largescal
dissemin
potenti
caus
social
disrupt
current
us
food
drug
administrationapprov
therapeut
agent
avail
prevent
treat
lethal
viral
infect
filoviru
surfac
glycoprotein
gp
heavili
glycosyl
contain
highmannos
result
mbl
bind
ebola
marburg
virus
mediat
complementdepend
viru
neutral
importantli
surfac
glycoprotein
structur
characterist
broad
group
virus
nlink
glycosyl
contribut
viral
virul
reason
mbl
treatment
like
safe
supraphysiolog
level
evalu
vivo
ebola
viru
model
explor
possibl
use
mbl
immunotherapeut
agent
result
show
supraphysiolog
dose
mbl
rescu
mice
lethal
challeng
administ
preor
postebola
viru
exposur
novel
paradigm
suggest
highdos
mbl
evalu
broadli
immunotherapeut
agent
wide
spectrum
glycosyl
pathogen
commercialgrad
rhmbl
provid
enzon
pharmaceut
human
mbl
concentr
complement
cleavag
activ
measur
describ
elsewher
pharmacokinet
rhmbl
concentrationtim
data
evalu
use
noncompartment
model
winnonlin
profession
edit
version
pharsight
area
curv
zero
infin
auc
valu
calcul
use
linear
trapezoid
method
use
valid
lethal
ebola
zair
mous
model
develop
us
armi
medic
research
institut
infecti
diseas
usamriid
doubl
plaquepurifi
mouseadapt
ebola
isol
gh
viru
inocul
intraperiton
ip
pfu
ld
produc
uniformli
lethal
diseas
mice
use
biosafeti
facil
research
conduct
complianc
anim
welfar
act
feder
regul
fulli
accredit
facil
assess
effect
rhmbl
viru
lethal
treat
ebola
virusinfect
mice
ip
either
mgkg
mgkg
rhmbl
twice
daili
hour
apart
day
day
viru
exposur
mice
treat
expos
pfu
mouseadapt
ebola
zair
either
hour
hour
first
dose
rhmbl
indic
figur
mice
assess
daili
chang
physic
appear
weight
viremia
assess
revers
transcriptionpolymeras
chain
reaction
rtpcr
plaqu
assay
describ
elsewher
antiebola
viru
antibodi
measur
use
standard
enzymelink
immunosorb
assay
elisa
standard
blood
count
evalu
coulter
c
diff
beckman
coulter
analysi
flow
cytometri
spleen
ground
singl
cell
suspens
bd
medimachin
tissu
grinder
incub
fc
block
bd
cell
wash
incub
antibodi
fitc
bd
bd
percp
ebio
pe
ebio
apc
bd
bd
cell
wash
pb
fix
bd
cytofix
data
immedi
acquir
bd
facscantoii
analyz
flowjo
version
bioplex
mous
cytokin
panel
assay
biorad
use
measur
multipl
cytokin
chemokin
growth
factor
serum
tissu
supernat
accord
manufactur
instruct
mice
surviv
initi
infect
test
ebolaspecif
serolog
respons
day
rechalleng
viru
dose
without
treatment
antibodi
titer
retest
day
later
previous
found
rhmbl
bound
ebola
zair
marburg
musok
envelop
gp
rhmbl
effect
block
ebola
gp
interact
dcsign
hiv
particl
lack
pseudotyp
ebola
marburg
gp
neutral
lectin
complement
pathway
develop
vivo
test
rhmbl
effect
determin
ngml
rhmbl
minimum
concentr
need
inhibit
infect
cell
use
ebola
gp
pseudotyp
lentivir
particl
inhibit
infect
vero
cell
use
recombin
ebola
zair
viru
mayinga
strain
egfp
data
shown
previous
found
singl
intraperiton
dose
lg
rhmbl
reconstitut
lectin
complement
pathway
mblknockout
mice
compar
pharmacokinet
paramet
tabl
intraperiton
administr
pfu
nativ
ebola
zair
viru
ld
uniformli
fatal
mice
treatment
lg
rhmbl
per
dose
everi
hour
fail
protect
mice
viru
inoculum
therefor
increas
rhmbl
lg
administ
everi
hour
day
start
either
hour
hour
ebola
viru
challeng
figur
treatment
start
hour
viru
infect
supraphysiolog
dose
increas
surviv
mice
sever
trial
figur
start
treatment
hour
viral
infect
compar
surviv
wildtyp
complement
compon
defici
mice
inhibitori
effect
mbl
ebola
viru
mediat
complement
cell
cultur
saw
increas
surviv
rhmbltreat
mice
surviv
depend
intact
complement
pathway
sinc
mice
surviv
figur
inocul
mice
show
sign
infect
accord
standard
observ
score
weight
loss
surviv
mice
detect
ebola
virusspecif
antibodi
day
infect
data
shown
monitor
effect
treatment
start
hour
infect
varieti
laboratori
indic
mean
white
blood
cell
count
cellsml
mbltreat
mice
n
compar
cellsml
day
infect
surviv
shamtreat
mice
n
averag
lymphocyt
count
also
higher
mbltreat
mice
compar
control
cellsml
vs
cellsml
respect
similar
trend
seen
platelet
count
averag
cell
ml
treatment
group
cellsml
control
differ
statist
signific
platelet
count
day
cellsml
vs
cellsml
p
figur
separ
experi
spleen
harvest
day
infect
shamtreat
mbltreat
mice
constitu
cell
popul
assay
flow
cytometri
number
splenic
cell
b
lymphocyt
granulocyt
higher
mbltreat
mice
vs
p
vs
p
respect
rna
viral
load
determin
rtpcr
blood
liver
spleen
day
infect
similar
shamand
rhmbltreat
mice
p
viru
titer
blood
gener
lower
day
rhmbltreat
mice
determin
plaqu
assay
p
figur
cytokin
chemokin
test
serum
liver
spleen
day
inocul
lower
valu
fluoresc
intens
unit
interleukin
il
vs
p
vs
p
vs
p
vs
p
vs
p
found
liver
homogen
rhmbltreat
mice
figur
test
protect
immun
seroposit
mice
surviv
initi
infect
rechalleng
nativ
ebola
viru
day
initi
infect
noteworthi
mbltreat
survivor
also
surviv
second
viral
challeng
similar
higher
immunoglobulin
g
antibodi
titer
seen
day
second
challeng
viru
figur
past
decad
approv
antivir
increas
nucleosid
analogu
well
drug
human
immunodefici
viru
hiv
hepat
c
viru
hcv
epidem
particularli
drove
antivir
discoveri
toward
ration
design
drug
target
specif
viral
enzym
although
approach
remark
effect
advent
newli
emerg
drugresist
virus
threaten
human
call
develop
broadli
activ
agent
target
viral
compon
share
among
virus
nglycosyl
viral
envelop
import
target
share
influenza
hiv
hcv
west
nile
viru
sarscov
hendra
viru
nipah
viru
filovirus
ebola
marburg
virus
assess
one
possibl
strategi
nglycosyl
virus
test
stringent
ebola
viru
infect
model
ld
mice
filoviru
infect
character
mark
lymphopenia
sever
degener
lymphoid
tissu
dysregul
dendrit
cell
function
cytokin
stormsal
hallmark
pathogen
subvert
innat
adapt
immun
respons
nevertheless
survivor
exhibit
detect
virusspecif
antibodi
respons
therefor
hypothes
administr
recombin
innat
immun
molecul
target
glycosyl
virus
might
bridg
infect
individu
recoveri
show
first
time
rhmbl
use
therapeut
agent
achiev
serum
concentr
mice
correspond
level
human
higher
averag
human
concentr
complement
cleav
activ
higher
baselin
valu
mice
result
confirm
previou
vitro
data
show
mbl
possess
complementdepend
intrins
antimicrobi
activ
biolog
respons
infect
mice
rhmbl
treatment
indic
strategi
target
main
pathogen
effect
ebola
virus
mbltreat
mice
higher
b
lymphocyt
granulocyt
count
demonstr
downregul
intrahepat
proinflammatori
cytokin
earli
cours
infect
figur
suggest
rhmbl
may
mitig
detriment
effect
characterist
cytokin
storm
mbltreat
mice
tend
greater
inhibit
viral
replic
day
infect
p
figur
import
rhmbl
treatment
bridg
surviv
mice
develop
effect
adapt
immun
respons
figur
futur
experi
need
scale
highdos
rhmbl
therapi
use
larger
anim
model
test
rhmbl
combin
promis
experiment
therapi
small
molecul
inhibitor
coagul
modul
antisens
technolog
therapeut
antibodi
note
rhmbl
administ
singl
intraperiton
inject
data
arithmet
mean
statist
differ
analyz
student
ttest
valu
p
consid
indic
statist
signific
differ
rhmbl
recombin
human
mannosebind
lectin
cytokin
postexposur
vaccin
summari
report
supraphysiolog
rhmbl
therapi
may
effect
immunotherapeut
strategi
ebola
viru
sinc
ebola
glycoprotein
potenti
model
glycosyl
virus
rhmbl
therapi
may
offer
novel
broadspectrum
antivir
approach
studi
support
grant
ev
nation
institut
health
nih
ev
addit
support
nih
grant
ggo
addit
support
defens
threat
reduct
agenc
medic
biolog
defens
research
program
therapeut
research
program
kt
receiv
addit
support
nih
grant
